Perbak Capital Partners LLP Gilead Sciences, Inc. Transaction History
Perbak Capital Partners LLP
- $135 Billion
- Q1 2025
A detailed history of Perbak Capital Partners LLP transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Perbak Capital Partners LLP holds 2,125 shares of GILD stock, worth $228,161. This represents 0.18% of its overall portfolio holdings.
Number of Shares
2,125Holding current value
$228,161% of portfolio
0.18%Shares
1 transactions
Others Institutions Holding GILD
# of Institutions
2,285Shares Held
997MCall Options Held
9.62MPut Options Held
10M-
Black Rock Inc. New York, NY121MShares$13 Billion0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA117MShares$12.6 Billion0.25% of portfolio
-
State Street Corp Boston, MA59.5MShares$6.39 Billion0.28% of portfolio
-
Capital Research Global Investors Los Angeles, CA54.6MShares$5.86 Billion1.39% of portfolio
-
Capital World Investors Los Angeles, CA53.5MShares$5.75 Billion1.01% of portfolio
About GILEAD SCIENCES, INC.
- Ticker GILD
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 1,253,369,984
- Market Cap $135B
- Description
- Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...